Insight, China's Pharmaceutical Industry

MicroPort NeuroScientific’s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China’s First Targeted-Release Self-Expanding System

MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting...

Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026

China Resources Pharmaceutical Group Limited (HKG: 3320) announced a definitive agreement to acquire 188,102,749 shares...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

Fineline Cube Jul 30, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1...

Others

Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US

Fineline Cube Jul 30, 2026

Xgene Pharmaceutical Inc. announced the successful completion of a RMB 250 million ($35 million) Series...

Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Fineline Cube Jul 30, 2026

Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to...

Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Fineline Cube Jul 29, 2026

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) announced plans to initiate a Phase Ib...

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Fineline Cube Jul 29, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced plans to establish a major new global R&D center...

Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Fineline Cube Jul 29, 2026

Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059)...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Fineline Cube Jul 29, 2026

Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug...

Company Drug

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Fineline Cube Jul 29, 2026

Shionogi & Co., Ltd. (TYO: 4507) announced the U.S. commercial availability of XOCOVA (ensitrelvir), an...

Company Drug

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Fineline Cube Jul 29, 2026

Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s...

Company Drug

Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials

Fineline Cube Jul 29, 2026

Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial...

Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026

TPMeds announced the successful completion of an Angel financing round amounting to tens of millions...

Company Drug

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

Fineline Cube Jul 29, 2026

AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet...

Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released a...

Company Drug

Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience

Fineline Cube Jul 29, 2026

Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced that its subsidiary GenSci has initiated...

Policy / Regulatory

China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations

Fineline Cube Jul 29, 2026

China’s National Medical Products Administration (NMPA) released the Administrative Measures for Medical Device Online Sales...

Policy / Regulatory

China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units

Fineline Cube Jul 29, 2026

China’s National Drug Joint Procurement Office released enterprise-related information for the 12th batch of national...

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026

HBM Holdings Limited (HKG: 2142) announced a strategic cooperation framework agreement with China National Pharmaceutical...

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Fineline Cube Jul 28, 2026

Antengene Corporation Limited (HKG: 6996) announced preliminary financial results for the six months ended June...

Insight, China's Pharmaceutical Industry

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

MicroPort NeuroScientific’s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China’s First Targeted-Release Self-Expanding System

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience

China’s NMPA Proposes Sweeping Reforms to Medical Device E-Commerce with New Draft Regulations

China’s 12th National Drug Procurement Round Attracts 500+ Companies, Targets 7.34 Billion Units

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

You Missed

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia